Company intelligence / Profile preview

Cerium Pharmaceuticals

Gaithersburg, Maryland, United Statesceriumpharma.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Cerium Pharmaceuticals has completed preclinical and Phase 1 studies demonstrating safety and tolerability of its lead candidate SNP-ACTH (1–39) Gel. The company received FDA Orphan Drug Designation for this product targeting PMN. It is currently enrolling patients in a multi-country Phase 3 trial comparing SNP-ACTH Gel to rituximab for first-line immunosuppressive treatment of moderate to high-risk PMN patients. No approved therapies exist for PMN, highlighting the unmet need addressed by this program[7][8][10].

Therapeutic areas: Nephrology
Modalities: Synthetic peptides (specifically synthetic ACTH)biologics[1][10]
Industry: Biotech

Drug pipeline

2 assets

corticotropin (Cerium Pharmaceuticals)

Approved

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Cerium Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cerium Pharmaceuticals.

Explore the full profile